ClinicalTrials.gg
CompletedNCT01423604RECAPUpdated Feb 12, 2018Results posted

Study of Ruxolitinib in Pancreatic Cancer Patients

A Phase 2 interventional study of Capecitabine and Ruxolitinib in Pancreatic Cancer, sponsored by Incyte Corporation. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-12.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Pancreatic Neoplasms by Incyte Corporation — 1 open to participants now, 2 under way, 1 of them phase 3. Pancreatic Neoplasms · Incyte Corporation.

Enrollment
5th of 10
136 · median 111
Started
2011
the only one that year
Phase 2
2 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 2 in phase 2, and was the 1st registered.

Pancreatic Neoplasms

3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

1 of the 10 studies in Pancreatic Neoplasms by Incyte Corporation is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pancreatic Neoplasms by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.

Read the detailed description

The study consisted of an open-label, safety run-in period that was composed of 1 patient cohort with 9 patients/cohort. This phase of the study determined the safety of the capecitabine/ruxolitinib combination in this patient population.

A randomized, double-blind study with two treatment arms was conducted once the safety run-in results from the first part of the study showed that the capecitabine/ruxolitinib combination was safe and additional patients could be treated. All patients have received capecitabine therapy in addition to the ruxolitinib or placebo (Study Drug).

Treatment for all patients consisted of repeating 21-day cycles. Capecitabine was self-administered for the first 14 days of each cycle, and the Study Drug was self-administered during the entire 21-day cycle. Treatment cycles continued as long as the regimen was tolerated and the patient did not meet any of the discontinuation criteria. In the event of disease progression, capecitabine therapy was discontinued but the Study Drug could continue to be administered. Subjects who discontinued treatment with the Study Drug continued to be followed to obtain information regarding subsequent treatment regimens and survival.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Metastatic pancreatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Diagnosis of pancreatic cancer; subjects must have had measurable, or evaluable disease that was confirmed
  • performance status of ≥ 60
  • Subjects must have failed gemcitabine treatment for metastatic pancreatic cancer:

    o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy in the event that the subject was intolerant to or ineligible to receive gemcitabine

  • ≥ 2 weeks elapsed from the completion of previous chemotherapy, and subjects must have recovered or been at new stable baseline from any related toxicities

Exclusion criteria

Exclusion Criteria:

  • More than 1 prior chemotherapy regimen (not including therapy) for disease
  • Evidence of central nervous system (CNS) metastases (unless stable for > 3 months) or history of uncontrolled seizures
  • Ongoing radiation therapy or prior radiation therapy administered as a treatment
  • Other active except basal or squamous carcinoma of the skin
  • Inability to swallow food or any condition of the upper GI tract that precluded administration of oral medications
  • Inadequate renal, hepatic and bone marrow function demonstrated by clinical observations and/or laboratory assessments
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Capecitabine and ruxolitinib

    Drug: Capecitabine · Drug: Ruxolitinib

  • Placebo comparator
    Capecitabine and placebo

    Drug: Capecitabine · Drug: Placebo

Interventions

  • Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)

  • Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)

  • DrugPlacebo

    Placebo matching ruxolitinib

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was measured as the length of time (in days) between the randomization date and the date of death.

    Time frame: Primary analysis includes study data from the start of the study (first dose for that subject) until the death of the subject (up to 8 months).

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival was defined as the length of time between the date of randomization and the earlier of death or progressive disease (PD), whichever was earlier, as assessed by RECIST. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: Analysis includes study data from the start of the study (first dose for that subject) until death or PD, whichever was earlier up to 8 months.

  2. Objective Response Rate

    Objective response rate (ORR) was defined as the percentage of participants with either a confirmed complete response (CR) or partial response (PR) measured by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria during the treatment period. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Measured every 4 weeks for duration of study treatment (up to 8 months)

  3. Durable Response Rate

    Durable response was defined as subjects with a response of Partial response (PR) or better at 2 subsequent measurements that were at least 4 weeks apart.

    Time frame: Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months)

  4. Summary of Clinical Benefit

    A subject was considered a clinical benefit responder if he/she met at least 1 of the following criteria: 1. Subject showed improvement in at least one of the following parameters on successive scheduled observations without worsening in the others: pain intensity, analgesic use, or performance status 2. Subject was stable or improved on the pain intensity, analgesic use, and performance status and had a ≥ 7% increase in body weight maintained for 2 consecutive reporting periods that was not because of fluid accumulation.

    Time frame: Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months)

07

Results

Posted Aug 29, 2016

Participant flow

The open-label, safety run-in (1 cohort) was designed to confirm the safety of the combination of ruxolitinib and capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas. The double-blind portion was 2 treatment groups randomized 1:1: ruxolitinib plus capecitabine or matching placebo plus capecitabine.

Safety Run-In
Participant flow — Safety Run-In
MilestoneRuxolitinibPlacebo
Started90
Completed00
Not completed90
Withdrew: Adverse event30
Withdrew: Death10
Withdrew: Physician decision10
Withdrew: Disease progression30
Withdrew: Patient decision10
Randomized
Participant flow — Randomized
MilestoneRuxolitinibPlacebo
Started6463
Completed10
Not completed6363
Withdrew: Adverse event410
Withdrew: Death10
Withdrew: Physician decision1613
Withdrew: Other - unspecified3731
Withdrew: Patient decision59

Outcome measures

PrimaryOverall Survival

Overall survival was measured as the length of time (in days) between the randomization date and the date of death.

Time frame:
Primary analysis includes study data from the start of the study (first dose for that subject) until the death of the subject (up to 8 months).
Reported as:
Median · days
Overall Survival
daysRuxolitinibPlacebo
Overall Survival136.5 (95.0 to 196.0)129.5 (71.0 to 179.0)
Statistical analysis
  • Ruxolitinib vs Placebo · Log Rank · p = 0.0494 (One-sided p-value.) · Hazard ratio (hr): 0.733 · 95% CI 0.506 to 1.061
  • Ruxolitinib vs Placebo · Log Rank · p = 0.0081 (One-sided p-value.) · Hazard ratio (hr): 0.502 · 95% CI 0.281 to 0.888
SecondaryProgression-Free Survival (PFS)

Progression-free survival was defined as the length of time between the date of randomization and the earlier of death or progressive disease (PD), whichever was earlier, as assessed by RECIST. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
Analysis includes study data from the start of the study (first dose for that subject) until death or PD, whichever was earlier up to 8 months.
Reported as:
Median · days
Progression-Free Survival (PFS)
daysRuxolitinibPlacebo
Progression-Free Survival (PFS)51.0 (42.0 to 84.0)46.0 (41.0 to 70.0)
Statistical analysis
  • Ruxolitinib vs Placebo · Cox proportional hazards model · p = 0.1340 (Two-sided p-value.) · Efron approximation of hazard ratio: 0.750 · 95% CI 0.513 to 1.094
SecondaryObjective Response Rate

Objective response rate (ORR) was defined as the percentage of participants with either a confirmed complete response (CR) or partial response (PR) measured by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria during the treatment period. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Measured every 4 weeks for duration of study treatment (up to 8 months)
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsRuxolitinibPlacebo
Overall response7.81.6
Complete response1.60.0
Partial response6.31.6
SecondaryDurable Response Rate

Durable response was defined as subjects with a response of Partial response (PR) or better at 2 subsequent measurements that were at least 4 weeks apart.

Time frame:
Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months)
Reported as:
Number · percentage of participants
Durable Response Rate
percentage of participantsRuxolitinibPlacebo
Durable Response Rate7.80.0
Statistical analysis
  • Ruxolitinib vs Placebo · Pearson's chi-square test · p = 0.0236
SecondarySummary of Clinical Benefit

A subject was considered a clinical benefit responder if he/she met at least 1 of the following criteria: 1. Subject showed improvement in at least one of the following parameters on successive scheduled observations without worsening in the others: pain intensity, analgesic use, or performance status 2. Subject was stable or improved on the pain intensity, analgesic use, and performance status and had a ≥ 7% increase in body weight maintained for 2 consecutive reporting periods that was not because of fluid accumulation.

Time frame:
Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months)
Reported as:
Number · percentage of participants
Summary of Clinical Benefit
percentage of participantsRuxolitinibPlacebo
Subjects with clinical benefit12.51.6
Pain intensity - Improved10.91.6
Analgesic use - Improved4.70.0
Karnofsky performance status - Improved3.10.0
Body weight - Improved3.10.0

Adverse events

Collected over From the start of the study (first dose for that subject) until the end of the Adverse Event (AE) period (30 days after the last dose) or death, whichever was earlier (up to 8 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib (Safety Run-In)—5/9 (55.6%)9/9 (100%)
Ruxolitinib—32/59 (54.2%)57/59 (96.6%)
Placebo—35/60 (58.3%)59/60 (98.3%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventRuxolitinib (Safety Run-In)RuxolitinibPlacebo
Abdominal painGastrointestinal disorders2/92/595/60
VomitingGastrointestinal disorders2/91/595/60
DiarrhoeaGastrointestinal disorders1/92/591/60
NauseaGastrointestinal disorders1/92/595/60
AstheniaGeneral disorders1/90/592/60
SepsisInfections and infestations1/91/590/60
Urinary tract infectionInfections and infestations1/90/591/60
International normalized ratio increasedInvestigations1/90/591/60
Failure to thriveMetabolism and nutrition disorders1/90/591/60
Cerebrovascular accidentNervous system disorders1/90/591/60
Most frequent other events
Showing 10 of 117
Most frequent other events
EventRuxolitinib (Safety Run-In)RuxolitinibPlacebo
AnemiaBlood and lymphatic system disorders7/930/5912/60
Abdominal painGastrointestinal disorders5/922/5923/60
VomitingGastrointestinal disorders5/914/5921/60
DehydrationMetabolism and nutrition disorders5/912/5910/60
FatigueGeneral disorders2/929/5926/60
NauseaGastrointestinal disorders4/921/5927/60
DiarrheaGastrointestinal disorders4/922/5917/60
StomatitisGastrointestinal disorders3/916/598/60
Decreased appetiteMetabolism and nutrition disorders2/912/5920/60
Edema peripheralMetabolism and nutrition disorders3/97/596/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Mean61.6 ± 9.465.7 ± 9.366.3 ± 9.866.0 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Female5232957
Male4413479
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Hispanic or Latino0156
Not Hispanic or Latino96258129
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
American Indian or Alaska Native0000
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American39618
White55454113
More than one race0000
Unknown or Not Reported0123
Height
Height(cm)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Mean171.67 ± 14.11171.29 ± 11.93168.27 ± 10.25169.78 ± 11.18
Weight
Weight(kg)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Mean75.051 ± 17.31775.014 ± 21.91469.299 ± 16.26072.156 ± 19.427
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Mean25.3 ± 4.20925.354 ± 6.33224.243 ± 4.23724.789 ± 5.394
Body surface area
Body surface area(m^2)Ruxolitinib - Safety Run-InRuxolitinibPlaceboTotal
Mean1.869 ± 0.2871.863 ± 0.2971.791 ± 0.2481.827 ± 0.275
08

Study locations

39 sites
  • Birmingham, Alabama, United States
  • Hot Springs, Arkansas, United States
  • Burbank, California, United States
  • Los Angeles, California, United States
  • Santa Monica, California, United States
  • Denver, Colorado, United States
  • Stamford, Connecticut, United States
  • Boynton Beach, Florida, United States
  • Fort Myers, Florida, United States
  • Saint Petersburg, Florida, United States
  • Arlington Heights, Illinois, United States
  • Elks Grove Village, Illinois, United States
  • Indianapolis, Indiana, United States
  • Sioux City, Iowa, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Worcester, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Novi, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Voorhees, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Lake Success, New York, United States
  • Durham, North Carolina, United States
  • Hickory, North Carolina, United States
  • Canton, Ohio, United States
  • Dayton, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Bend, Oregon, United States
  • Portland, Oregon, United States
  • Danville, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Knoxville, Tennessee, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Green Bay, Wisconsin, United States
09

References and documents

Publications

  • Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015 Dec 1;33(34):4039-47. doi: 10.1200/JCO.2015.61.4578. Epub 2015 Sep 8. PubMed 26351344 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jun 2013 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 3 years 2 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2011
First posted
Aug 26, 2011
Start
Jul 2011
Primary completionActual
Jun 2013
CompletionActual
Nov 2016
Results delay requested
Apr 4, 2014
Results first posted
Aug 29, 2016
Last update
Feb 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01423604
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 26, 2011
Start date
Jul 2011
Primary completion
Jun 2013
Completion
Nov 2016
Results posted
Aug 29, 2016
Last update
Feb 12, 2018

Study contacts

William Williams, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion